Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024